New treatment options for lupus - a focus on belimumab
New treatment options for lupus - a focus on belimumab
About this item
Full title
Author / Creator
Publisher
New Zealand: Dove Medical Press Limited
Journal title
Language
English
Formats
Publication information
Publisher
New Zealand: Dove Medical Press Limited
Subjects
More information
Scope and Contents
Contents
Belimumab is the first biologic approved for patients with systemic lupus erythematosus (SLE). Belimumab is the first of a new class of drug targeting B cell-stimulating factors or their receptors to reach the market. Its target, BLyS, also known as BAFF (B cell-activating factor from the tumor necrosis factor family), is a type II transmembrane pr...
Alternative Titles
Full title
New treatment options for lupus - a focus on belimumab
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3277870
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3277870
Other Identifiers
ISSN
1178-203X,1176-6336
E-ISSN
1178-203X
DOI
10.2147/TCRM.S19819
